Pasithea Therapeutics (KTTA) Share-based Compensation (2021 - 2024)
Historic Share-based Compensation for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to $118383.0.
- Pasithea Therapeutics' Share-based Compensation rose 6926.37% to $118383.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $720860.0, marking a year-over-year increase of 3252.05%. This contributed to the annual value of $773693.0 for FY2024, which is 3063.2% up from last year.
- Pasithea Therapeutics' Share-based Compensation amounted to $118383.0 in Q4 2024, which was up 6926.37% from $121000.0 recorded in Q3 2024.
- Pasithea Therapeutics' 5-year Share-based Compensation high stood at $450000.0 for Q3 2021, and its period low was $69940.0 during Q4 2023.
- Over the past 4 years, Pasithea Therapeutics' median Share-based Compensation value was $135315.0 (recorded in 2022), while the average stood at $179044.6.
- Per our database at Business Quant, Pasithea Therapeutics' Share-based Compensation plummeted by 7777.78% in 2022 and then skyrocketed by 9572.65% in 2024.
- Over the past 4 years, Pasithea Therapeutics' Share-based Compensation (Quarter) stood at $450000.0 in 2021, then plummeted by 65.29% to $156174.0 in 2022, then tumbled by 55.22% to $69940.0 in 2023, then surged by 69.26% to $118383.0 in 2024.
- Its Share-based Compensation stands at $118383.0 for Q4 2024, versus $121000.0 for Q3 2024 and $135000.0 for Q2 2024.